Setting the Stage: Immunotherapy’s Impact and EMPOWER-Lung 1 Study Design
Panelists discuss how over the last five years, immunotherapy, particularly PD-1 inhibitors, has revolutionized advanced non-small cell lung cancer (NSCLC) treatment, offering promising first-line therapy options. Prior to the EMPOWER-Lung 1 study, PD-1 inhibitors showed improved survival outcomes as monotherapy. Treatment considerations have since evolved to incorporate patient-specific factors, optimizing therapy based on individual characteristics.
Video content above is prompted by the following:
- Over the last five years, how has the emergence of immunotherapy in advanced NSCLC shifted the treatment paradigm in terms of the use of PD-1 inhibitors as first-line therapy?
- Prior to this study, what was known about the survival outcomes of patients receiving PD-1 inhibitors when used as monotherapy in the treatment of advanced NSCLC?
- How have treatment considerations changed regarding the characteristics of patients receiving PD-1 inhibitors since the initiation of this trial?
Medicaid Expansion Linked To Timelier Lung Cancer Surgery and Access to High-Volume Hospitals
April 17th 2025New research shows that Medicaid expansion was linked to a 2.1% increase in timely lung cancer surgeries and a 2.8% rise in procedures at high-volume hospitals, highlighting how policy changes can impact cancer care access.
Read More
Chest X-rays Linked to Earlier Lung Cancer Detection and Improved Outcomes
April 7th 2025A new study in England shows a strong link between higher rates of chest x-ray referrals in general practice patients with symptoms, such as persistent cough, and earlier lung cancer diagnoses, along with improved outcomes.
Read More
Study Finds Adherence to Annual Lung Cancer Screening Linked to Higher Detection Rates
March 18th 2025Researchers found that adherence to the first and second annual screenings was 61% and 51%, respectively, with higher lung cancer detection rates observed in those who followed through on these screenings.
Read More
Regeneron Canada Reaches New Agreement Deal for Cancer Drug Libtayo
March 7th 2025The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in different provinces and territories will cover the drug's cost for patients, according to a news release by Regeneron Canada.
Read More
